Please assess the completion status of the following clinical trial:

Trial Title: Scottish and Newcastle Anti-emetic Pre-treatment for Paracetamol Poisoning Study (SNAP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Any patient admitted to hospital within 36 hours of a single acute paracetamol overdose; AND~* Requires treatment with acetylcysteine.~These patients will include:~* Patients with no risk factors and timed paracetamol concentrations above the 200-line on the UK paracetamol overdose treatment nomogram.~* Patients with at least 1 risk factor and timed paracetamol concentrations above the 100-line on the UK paracetamol overdose treatment nomogram~* Patients presenting \>8 hours, and at risk of liver damage based on history of dose ingested (BNF) that need immediate treatment~Risk factors are defined as follows:~* Nutritional deficiency, malnourished and/or debilitating disease: acute or chronic starvation, eating disorders, cachexia, malabsorption syndromes, AIDS, cystic fibrosis, hepatitis C, chronic alcoholism.~* Enzyme induction: use of drugs with this property (carbamazepine, rifampicin, barbiturates, phenytoin, rifabutin, efavirenz, nevirapine, St John's Wort; regular consumption of ethanol above advised amounts.~Exclusion Criteria:~Patients:~* \< 16 years old~* Detained under the Mental Health Act~* With known permanent cognitive impairment~* With a life-threatening illness~* Who are known to be pregnant~* Who have previously participated in the study~* Unreliable history of paracetamol overdose~* Vomiting and requiring treatment antiemetic prior to randomisation~* Presenting after 36 hours of a single acute paracetamol overdose~* Presenting after taking a staggered paracetamol overdose (defined as when the overdose of paracetamol is taken over a period of more than 2 hours)~* Who take anticoagulants (e.g. warfarin) therapeutically or have taken an overdose of anticoagulants~* Who, in the opinion of the responsible clinician/nurse, are unlikely to complete the full course of acetylcysteine e.g. expressing wish to self-discharge~* Who in the opinion of the responsible clinician/nurse are unable to complete the initial questionnaire either themselves or with nurse assistance.~* Who have a history of hypersensitivity to 5HT3 antagonists~* Non-English speaking patients. (Trial information material will only be produced in English in view of the known and stable demographic of the Edinburgh and Newcastle self harm population)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ondansetron /acetylcysteine 20.25h (Type: OTHER): Ondansetron followed by conventional acetylcysteine regimen
- Placebo/acetylcysteine 20.25h (Type: OTHER): placebo followed by conventional acetylcysteine regimen
- Ondansetron/acetylcysteine 12h (Type: OTHER): ondansetron followed by modified acetylcysteine regimen
- Placebo/acetylcysteine 12h (Type: OTHER): placebo followed by modified acetylcysteine regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).